|NASDAQ: GLMD||Healthcare / Biotechnology / Israel|
|0.4265||-0.0434||-9.24%||Vol 22.93K||1Y Perf -70.45%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||1.00||Analyst Rating||Hold 3.00|
|Potential %||134.47||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||8.82||Earnings Rating||Sell|
|Market Cap||9.00M||Earnings Date||16th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||16th May 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||36.88K|
|Avg. Monthly Volume||31.71K|
|Avg. Quarterly Volume||85.81K|
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) stock closed at 0.4265 per share at the end of the most recent trading day (a -9.24% change compared to the prior day closing price) with a volume of 22.93K shares and market capitalization of 9.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 21 people. Galmed Pharmaceuticals Ltd. CEO is Allen Baharaff.
The one-year performance of Galmed Pharmaceuticals Ltd. stock is -70.45%, while year-to-date (YTD) performance is -14.7%. GLMD stock has a five-year performance of -92.34%. Its 52-week range is between 0.29 and 1.8381, which gives GLMD stock a 52-week price range ratio of 8.82%
Galmed Pharmaceuticals Ltd. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 1.28, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.67%, a ROC of -84.33% and a ROE of -95.16%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Galmed Pharmaceuticals Ltd., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Galmed Pharmaceuticals Ltd.’s next earnings report date is 16th May 2023.
The consensus rating of Wall Street analysts for Galmed Pharmaceuticals Ltd. is Hold (3), with a target price of $1, which is +134.47% compared to the current price. The earnings rating for Galmed Pharmaceuticals Ltd. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Galmed Pharmaceuticals Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Galmed Pharmaceuticals Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.34, ATR14 : 0.05, CCI20 : -32.70, Chaikin Money Flow : 0.04, MACD : -0.03, Money Flow Index : 22.95, ROC : -8.71, RSI : 41.45, STOCH (14,3) : 50.86, STOCH RSI : 0.55, UO : 66.66, Williams %R : -49.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Galmed Pharmaceuticals Ltd. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
CEO: Allen Baharaff
Telephone: +972 36938448
Address: 16 Tiomkin Street, Tel Aviv 6578317, , IL
Number of employees: 21
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.